Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
4,973
archived clinical trials in
High Cholesterol

A Study of LY2484595 in Patients With High LDL-C or Low HDL-C
A Phase 2 Efficacy and Safety Study of LY2484595 Alone and in Combination With Atorvastatin, Simvastatin, and Rosuvastatin in Patients With Hypercholesterolemia or Low HDL-C
Status: Enrolling
Updated:  2/18/2018
Clinical Research Facility
mi
from
Waterloo, IA
A Study of LY2484595 in Patients With High LDL-C or Low HDL-C
A Phase 2 Efficacy and Safety Study of LY2484595 Alone and in Combination With Atorvastatin, Simvastatin, and Rosuvastatin in Patients With Hypercholesterolemia or Low HDL-C
Status: Enrolling
Updated: 2/18/2018
Clinical Research Facility
mi
from
Waterloo, IA
Click here to add this to my saved trials
A Study of LY2484595 in Patients With High LDL-C or Low HDL-C
A Phase 2 Efficacy and Safety Study of LY2484595 Alone and in Combination With Atorvastatin, Simvastatin, and Rosuvastatin in Patients With Hypercholesterolemia or Low HDL-C
Status: Enrolling
Updated:  2/18/2018
Clinical Research Facility
mi
from
Wichita, KA
A Study of LY2484595 in Patients With High LDL-C or Low HDL-C
A Phase 2 Efficacy and Safety Study of LY2484595 Alone and in Combination With Atorvastatin, Simvastatin, and Rosuvastatin in Patients With Hypercholesterolemia or Low HDL-C
Status: Enrolling
Updated: 2/18/2018
Clinical Research Facility
mi
from
Wichita, KA
Click here to add this to my saved trials
A Study of LY2484595 in Patients With High LDL-C or Low HDL-C
A Phase 2 Efficacy and Safety Study of LY2484595 Alone and in Combination With Atorvastatin, Simvastatin, and Rosuvastatin in Patients With Hypercholesterolemia or Low HDL-C
Status: Enrolling
Updated:  2/18/2018
Clinical Research Facility
mi
from
Lexington, KY
A Study of LY2484595 in Patients With High LDL-C or Low HDL-C
A Phase 2 Efficacy and Safety Study of LY2484595 Alone and in Combination With Atorvastatin, Simvastatin, and Rosuvastatin in Patients With Hypercholesterolemia or Low HDL-C
Status: Enrolling
Updated: 2/18/2018
Clinical Research Facility
mi
from
Lexington, KY
Click here to add this to my saved trials
A Study of LY2484595 in Patients With High LDL-C or Low HDL-C
A Phase 2 Efficacy and Safety Study of LY2484595 Alone and in Combination With Atorvastatin, Simvastatin, and Rosuvastatin in Patients With Hypercholesterolemia or Low HDL-C
Status: Enrolling
Updated:  2/18/2018
Clinical Research Facility
mi
from
Auburn, ME
A Study of LY2484595 in Patients With High LDL-C or Low HDL-C
A Phase 2 Efficacy and Safety Study of LY2484595 Alone and in Combination With Atorvastatin, Simvastatin, and Rosuvastatin in Patients With Hypercholesterolemia or Low HDL-C
Status: Enrolling
Updated: 2/18/2018
Clinical Research Facility
mi
from
Auburn, ME
Click here to add this to my saved trials
A Study of LY2484595 in Patients With High LDL-C or Low HDL-C
A Phase 2 Efficacy and Safety Study of LY2484595 Alone and in Combination With Atorvastatin, Simvastatin, and Rosuvastatin in Patients With Hypercholesterolemia or Low HDL-C
Status: Enrolling
Updated:  2/18/2018
Clinical Research Facility
mi
from
Baltimore, MD
A Study of LY2484595 in Patients With High LDL-C or Low HDL-C
A Phase 2 Efficacy and Safety Study of LY2484595 Alone and in Combination With Atorvastatin, Simvastatin, and Rosuvastatin in Patients With Hypercholesterolemia or Low HDL-C
Status: Enrolling
Updated: 2/18/2018
Clinical Research Facility
mi
from
Baltimore, MD
Click here to add this to my saved trials
A Study of LY2484595 in Patients With High LDL-C or Low HDL-C
A Phase 2 Efficacy and Safety Study of LY2484595 Alone and in Combination With Atorvastatin, Simvastatin, and Rosuvastatin in Patients With Hypercholesterolemia or Low HDL-C
Status: Enrolling
Updated:  2/18/2018
Clinical Research Facility
mi
from
Picayune, MS
A Study of LY2484595 in Patients With High LDL-C or Low HDL-C
A Phase 2 Efficacy and Safety Study of LY2484595 Alone and in Combination With Atorvastatin, Simvastatin, and Rosuvastatin in Patients With Hypercholesterolemia or Low HDL-C
Status: Enrolling
Updated: 2/18/2018
Clinical Research Facility
mi
from
Picayune, MS
Click here to add this to my saved trials
A Study of LY2484595 in Patients With High LDL-C or Low HDL-C
A Phase 2 Efficacy and Safety Study of LY2484595 Alone and in Combination With Atorvastatin, Simvastatin, and Rosuvastatin in Patients With Hypercholesterolemia or Low HDL-C
Status: Enrolling
Updated:  2/18/2018
Clinical Research Facility
mi
from
Edison, NJ
A Study of LY2484595 in Patients With High LDL-C or Low HDL-C
A Phase 2 Efficacy and Safety Study of LY2484595 Alone and in Combination With Atorvastatin, Simvastatin, and Rosuvastatin in Patients With Hypercholesterolemia or Low HDL-C
Status: Enrolling
Updated: 2/18/2018
Clinical Research Facility
mi
from
Edison, NJ
Click here to add this to my saved trials
A Study of LY2484595 in Patients With High LDL-C or Low HDL-C
A Phase 2 Efficacy and Safety Study of LY2484595 Alone and in Combination With Atorvastatin, Simvastatin, and Rosuvastatin in Patients With Hypercholesterolemia or Low HDL-C
Status: Enrolling
Updated:  2/18/2018
Clinical Research Facility
mi
from
Endwell, NY
A Study of LY2484595 in Patients With High LDL-C or Low HDL-C
A Phase 2 Efficacy and Safety Study of LY2484595 Alone and in Combination With Atorvastatin, Simvastatin, and Rosuvastatin in Patients With Hypercholesterolemia or Low HDL-C
Status: Enrolling
Updated: 2/18/2018
Clinical Research Facility
mi
from
Endwell, NY
Click here to add this to my saved trials
A Study of LY2484595 in Patients With High LDL-C or Low HDL-C
A Phase 2 Efficacy and Safety Study of LY2484595 Alone and in Combination With Atorvastatin, Simvastatin, and Rosuvastatin in Patients With Hypercholesterolemia or Low HDL-C
Status: Enrolling
Updated:  2/18/2018
Clinical Research Facility
mi
from
Cary, NC
A Study of LY2484595 in Patients With High LDL-C or Low HDL-C
A Phase 2 Efficacy and Safety Study of LY2484595 Alone and in Combination With Atorvastatin, Simvastatin, and Rosuvastatin in Patients With Hypercholesterolemia or Low HDL-C
Status: Enrolling
Updated: 2/18/2018
Clinical Research Facility
mi
from
Cary, NC
Click here to add this to my saved trials
A Study of LY2484595 in Patients With High LDL-C or Low HDL-C
A Phase 2 Efficacy and Safety Study of LY2484595 Alone and in Combination With Atorvastatin, Simvastatin, and Rosuvastatin in Patients With Hypercholesterolemia or Low HDL-C
Status: Enrolling
Updated:  2/18/2018
Clinical Research Facility
mi
from
Charlotte, NC
A Study of LY2484595 in Patients With High LDL-C or Low HDL-C
A Phase 2 Efficacy and Safety Study of LY2484595 Alone and in Combination With Atorvastatin, Simvastatin, and Rosuvastatin in Patients With Hypercholesterolemia or Low HDL-C
Status: Enrolling
Updated: 2/18/2018
Clinical Research Facility
mi
from
Charlotte, NC
Click here to add this to my saved trials
A Study of LY2484595 in Patients With High LDL-C or Low HDL-C
A Phase 2 Efficacy and Safety Study of LY2484595 Alone and in Combination With Atorvastatin, Simvastatin, and Rosuvastatin in Patients With Hypercholesterolemia or Low HDL-C
Status: Enrolling
Updated:  2/18/2018
Clinical Research Facility
mi
from
Greensboro, NC
A Study of LY2484595 in Patients With High LDL-C or Low HDL-C
A Phase 2 Efficacy and Safety Study of LY2484595 Alone and in Combination With Atorvastatin, Simvastatin, and Rosuvastatin in Patients With Hypercholesterolemia or Low HDL-C
Status: Enrolling
Updated: 2/18/2018
Clinical Research Facility
mi
from
Greensboro, NC
Click here to add this to my saved trials
A Study of LY2484595 in Patients With High LDL-C or Low HDL-C
A Phase 2 Efficacy and Safety Study of LY2484595 Alone and in Combination With Atorvastatin, Simvastatin, and Rosuvastatin in Patients With Hypercholesterolemia or Low HDL-C
Status: Enrolling
Updated:  2/18/2018
Clinical Research Facility
mi
from
Hickory, NC
A Study of LY2484595 in Patients With High LDL-C or Low HDL-C
A Phase 2 Efficacy and Safety Study of LY2484595 Alone and in Combination With Atorvastatin, Simvastatin, and Rosuvastatin in Patients With Hypercholesterolemia or Low HDL-C
Status: Enrolling
Updated: 2/18/2018
Clinical Research Facility
mi
from
Hickory, NC
Click here to add this to my saved trials
A Study of LY2484595 in Patients With High LDL-C or Low HDL-C
A Phase 2 Efficacy and Safety Study of LY2484595 Alone and in Combination With Atorvastatin, Simvastatin, and Rosuvastatin in Patients With Hypercholesterolemia or Low HDL-C
Status: Enrolling
Updated:  2/18/2018
Clinical Research Facility
mi
from
Raleigh, NC
A Study of LY2484595 in Patients With High LDL-C or Low HDL-C
A Phase 2 Efficacy and Safety Study of LY2484595 Alone and in Combination With Atorvastatin, Simvastatin, and Rosuvastatin in Patients With Hypercholesterolemia or Low HDL-C
Status: Enrolling
Updated: 2/18/2018
Clinical Research Facility
mi
from
Raleigh, NC
Click here to add this to my saved trials
A Study of LY2484595 in Patients With High LDL-C or Low HDL-C
A Phase 2 Efficacy and Safety Study of LY2484595 Alone and in Combination With Atorvastatin, Simvastatin, and Rosuvastatin in Patients With Hypercholesterolemia or Low HDL-C
Status: Enrolling
Updated:  2/18/2018
Clinical Research Facility
mi
from
Salisbury, NC
A Study of LY2484595 in Patients With High LDL-C or Low HDL-C
A Phase 2 Efficacy and Safety Study of LY2484595 Alone and in Combination With Atorvastatin, Simvastatin, and Rosuvastatin in Patients With Hypercholesterolemia or Low HDL-C
Status: Enrolling
Updated: 2/18/2018
Clinical Research Facility
mi
from
Salisbury, NC
Click here to add this to my saved trials
A Study of LY2484595 in Patients With High LDL-C or Low HDL-C
A Phase 2 Efficacy and Safety Study of LY2484595 Alone and in Combination With Atorvastatin, Simvastatin, and Rosuvastatin in Patients With Hypercholesterolemia or Low HDL-C
Status: Enrolling
Updated:  2/18/2018
Clinical Research Facility
mi
from
Wilmington, NC
A Study of LY2484595 in Patients With High LDL-C or Low HDL-C
A Phase 2 Efficacy and Safety Study of LY2484595 Alone and in Combination With Atorvastatin, Simvastatin, and Rosuvastatin in Patients With Hypercholesterolemia or Low HDL-C
Status: Enrolling
Updated: 2/18/2018
Clinical Research Facility
mi
from
Wilmington, NC
Click here to add this to my saved trials
A Study of LY2484595 in Patients With High LDL-C or Low HDL-C
A Phase 2 Efficacy and Safety Study of LY2484595 Alone and in Combination With Atorvastatin, Simvastatin, and Rosuvastatin in Patients With Hypercholesterolemia or Low HDL-C
Status: Enrolling
Updated:  2/18/2018
Clinical Research Facility
mi
from
Winston-Salem, NC
A Study of LY2484595 in Patients With High LDL-C or Low HDL-C
A Phase 2 Efficacy and Safety Study of LY2484595 Alone and in Combination With Atorvastatin, Simvastatin, and Rosuvastatin in Patients With Hypercholesterolemia or Low HDL-C
Status: Enrolling
Updated: 2/18/2018
Clinical Research Facility
mi
from
Winston-Salem, NC
Click here to add this to my saved trials
A Study of LY2484595 in Patients With High LDL-C or Low HDL-C
A Phase 2 Efficacy and Safety Study of LY2484595 Alone and in Combination With Atorvastatin, Simvastatin, and Rosuvastatin in Patients With Hypercholesterolemia or Low HDL-C
Status: Enrolling
Updated:  2/18/2018
Clinical Research Facility
mi
from
Philadelphia, PA
A Study of LY2484595 in Patients With High LDL-C or Low HDL-C
A Phase 2 Efficacy and Safety Study of LY2484595 Alone and in Combination With Atorvastatin, Simvastatin, and Rosuvastatin in Patients With Hypercholesterolemia or Low HDL-C
Status: Enrolling
Updated: 2/18/2018
Clinical Research Facility
mi
from
Philadelphia, PA
Click here to add this to my saved trials
A Study of LY2484595 in Patients With High LDL-C or Low HDL-C
A Phase 2 Efficacy and Safety Study of LY2484595 Alone and in Combination With Atorvastatin, Simvastatin, and Rosuvastatin in Patients With Hypercholesterolemia or Low HDL-C
Status: Enrolling
Updated:  2/18/2018
Clinical Research Facility
mi
from
Red Lion, PA
A Study of LY2484595 in Patients With High LDL-C or Low HDL-C
A Phase 2 Efficacy and Safety Study of LY2484595 Alone and in Combination With Atorvastatin, Simvastatin, and Rosuvastatin in Patients With Hypercholesterolemia or Low HDL-C
Status: Enrolling
Updated: 2/18/2018
Clinical Research Facility
mi
from
Red Lion, PA
Click here to add this to my saved trials
A Study of LY2484595 in Patients With High LDL-C or Low HDL-C
A Phase 2 Efficacy and Safety Study of LY2484595 Alone and in Combination With Atorvastatin, Simvastatin, and Rosuvastatin in Patients With Hypercholesterolemia or Low HDL-C
Status: Enrolling
Updated:  2/18/2018
Clinical Research Facility
mi
from
Yardley, PA
A Study of LY2484595 in Patients With High LDL-C or Low HDL-C
A Phase 2 Efficacy and Safety Study of LY2484595 Alone and in Combination With Atorvastatin, Simvastatin, and Rosuvastatin in Patients With Hypercholesterolemia or Low HDL-C
Status: Enrolling
Updated: 2/18/2018
Clinical Research Facility
mi
from
Yardley, PA
Click here to add this to my saved trials
A Study of LY2484595 in Patients With High LDL-C or Low HDL-C
A Phase 2 Efficacy and Safety Study of LY2484595 Alone and in Combination With Atorvastatin, Simvastatin, and Rosuvastatin in Patients With Hypercholesterolemia or Low HDL-C
Status: Enrolling
Updated:  2/18/2018
Clinical Research Facility
mi
from
Greer, SC
A Study of LY2484595 in Patients With High LDL-C or Low HDL-C
A Phase 2 Efficacy and Safety Study of LY2484595 Alone and in Combination With Atorvastatin, Simvastatin, and Rosuvastatin in Patients With Hypercholesterolemia or Low HDL-C
Status: Enrolling
Updated: 2/18/2018
Clinical Research Facility
mi
from
Greer, SC
Click here to add this to my saved trials
A Study of LY2484595 in Patients With High LDL-C or Low HDL-C
A Phase 2 Efficacy and Safety Study of LY2484595 Alone and in Combination With Atorvastatin, Simvastatin, and Rosuvastatin in Patients With Hypercholesterolemia or Low HDL-C
Status: Enrolling
Updated:  2/18/2018
Clinical Research Facility
mi
from
Mount Pleasant, SC
A Study of LY2484595 in Patients With High LDL-C or Low HDL-C
A Phase 2 Efficacy and Safety Study of LY2484595 Alone and in Combination With Atorvastatin, Simvastatin, and Rosuvastatin in Patients With Hypercholesterolemia or Low HDL-C
Status: Enrolling
Updated: 2/18/2018
Clinical Research Facility
mi
from
Mount Pleasant, SC
Click here to add this to my saved trials
A Study of LY2484595 in Patients With High LDL-C or Low HDL-C
A Phase 2 Efficacy and Safety Study of LY2484595 Alone and in Combination With Atorvastatin, Simvastatin, and Rosuvastatin in Patients With Hypercholesterolemia or Low HDL-C
Status: Enrolling
Updated:  2/18/2018
Clinical Research Facility
mi
from
Simpsonville, SC
A Study of LY2484595 in Patients With High LDL-C or Low HDL-C
A Phase 2 Efficacy and Safety Study of LY2484595 Alone and in Combination With Atorvastatin, Simvastatin, and Rosuvastatin in Patients With Hypercholesterolemia or Low HDL-C
Status: Enrolling
Updated: 2/18/2018
Clinical Research Facility
mi
from
Simpsonville, SC
Click here to add this to my saved trials
A Study of LY2484595 in Patients With High LDL-C or Low HDL-C
A Phase 2 Efficacy and Safety Study of LY2484595 Alone and in Combination With Atorvastatin, Simvastatin, and Rosuvastatin in Patients With Hypercholesterolemia or Low HDL-C
Status: Enrolling
Updated:  2/18/2018
Clinical Research Facility
mi
from
Bristol, TN
A Study of LY2484595 in Patients With High LDL-C or Low HDL-C
A Phase 2 Efficacy and Safety Study of LY2484595 Alone and in Combination With Atorvastatin, Simvastatin, and Rosuvastatin in Patients With Hypercholesterolemia or Low HDL-C
Status: Enrolling
Updated: 2/18/2018
Clinical Research Facility
mi
from
Bristol, TN
Click here to add this to my saved trials
A Study of LY2484595 in Patients With High LDL-C or Low HDL-C
A Phase 2 Efficacy and Safety Study of LY2484595 Alone and in Combination With Atorvastatin, Simvastatin, and Rosuvastatin in Patients With Hypercholesterolemia or Low HDL-C
Status: Enrolling
Updated:  2/18/2018
Clinical Research Facility
mi
from
Kingsport, TN
A Study of LY2484595 in Patients With High LDL-C or Low HDL-C
A Phase 2 Efficacy and Safety Study of LY2484595 Alone and in Combination With Atorvastatin, Simvastatin, and Rosuvastatin in Patients With Hypercholesterolemia or Low HDL-C
Status: Enrolling
Updated: 2/18/2018
Clinical Research Facility
mi
from
Kingsport, TN
Click here to add this to my saved trials
A Study of LY2484595 in Patients With High LDL-C or Low HDL-C
A Phase 2 Efficacy and Safety Study of LY2484595 Alone and in Combination With Atorvastatin, Simvastatin, and Rosuvastatin in Patients With Hypercholesterolemia or Low HDL-C
Status: Enrolling
Updated:  2/18/2018
Clinical Research Facility
mi
from
Dallas, TX
A Study of LY2484595 in Patients With High LDL-C or Low HDL-C
A Phase 2 Efficacy and Safety Study of LY2484595 Alone and in Combination With Atorvastatin, Simvastatin, and Rosuvastatin in Patients With Hypercholesterolemia or Low HDL-C
Status: Enrolling
Updated: 2/18/2018
Clinical Research Facility
mi
from
Dallas, TX
Click here to add this to my saved trials
A Study of LY2484595 in Patients With High LDL-C or Low HDL-C
A Phase 2 Efficacy and Safety Study of LY2484595 Alone and in Combination With Atorvastatin, Simvastatin, and Rosuvastatin in Patients With Hypercholesterolemia or Low HDL-C
Status: Enrolling
Updated:  2/18/2018
Clinical Research Facility
mi
from
Houston, TX
A Study of LY2484595 in Patients With High LDL-C or Low HDL-C
A Phase 2 Efficacy and Safety Study of LY2484595 Alone and in Combination With Atorvastatin, Simvastatin, and Rosuvastatin in Patients With Hypercholesterolemia or Low HDL-C
Status: Enrolling
Updated: 2/18/2018
Clinical Research Facility
mi
from
Houston, TX
Click here to add this to my saved trials
A Study of LY2484595 in Patients With High LDL-C or Low HDL-C
A Phase 2 Efficacy and Safety Study of LY2484595 Alone and in Combination With Atorvastatin, Simvastatin, and Rosuvastatin in Patients With Hypercholesterolemia or Low HDL-C
Status: Enrolling
Updated:  2/18/2018
Clinical Research Facility
mi
from
Tacoma, WA
A Study of LY2484595 in Patients With High LDL-C or Low HDL-C
A Phase 2 Efficacy and Safety Study of LY2484595 Alone and in Combination With Atorvastatin, Simvastatin, and Rosuvastatin in Patients With Hypercholesterolemia or Low HDL-C
Status: Enrolling
Updated: 2/18/2018
Clinical Research Facility
mi
from
Tacoma, WA
Click here to add this to my saved trials
A Study of LY2484595 in Patients With High LDL-C or Low HDL-C
A Phase 2 Efficacy and Safety Study of LY2484595 Alone and in Combination With Atorvastatin, Simvastatin, and Rosuvastatin in Patients With Hypercholesterolemia or Low HDL-C
Status: Enrolling
Updated:  2/18/2018
Clinical Research Facility
mi
from
Oregon, WI
A Study of LY2484595 in Patients With High LDL-C or Low HDL-C
A Phase 2 Efficacy and Safety Study of LY2484595 Alone and in Combination With Atorvastatin, Simvastatin, and Rosuvastatin in Patients With Hypercholesterolemia or Low HDL-C
Status: Enrolling
Updated: 2/18/2018
Clinical Research Facility
mi
from
Oregon, WI
Click here to add this to my saved trials
A Study of LY2484595 in Patients With High LDL-C or Low HDL-C
A Phase 2 Efficacy and Safety Study of LY2484595 Alone and in Combination With Atorvastatin, Simvastatin, and Rosuvastatin in Patients With Hypercholesterolemia or Low HDL-C
Status: Enrolling
Updated:  2/18/2018
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
mi
from
Ballerup,
A Study of LY2484595 in Patients With High LDL-C or Low HDL-C
A Phase 2 Efficacy and Safety Study of LY2484595 Alone and in Combination With Atorvastatin, Simvastatin, and Rosuvastatin in Patients With Hypercholesterolemia or Low HDL-C
Status: Enrolling
Updated: 2/18/2018
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
mi
from
Ballerup,
Click here to add this to my saved trials
Evaluate Low Doses of AEGR-733 on Hepatic Fat Accumulation by MRS
A Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate Low Doses of the MTP-Inhibitor AEGR-733 on Hepatic Fat Accumulation as Measured by Magnetic Resonance Spectroscopy
Status: Enrolling
Updated:  2/21/2018
Scripps Clinic
mi
from
San Diego, CA
Evaluate Low Doses of AEGR-733 on Hepatic Fat Accumulation by MRS
A Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate Low Doses of the MTP-Inhibitor AEGR-733 on Hepatic Fat Accumulation as Measured by Magnetic Resonance Spectroscopy
Status: Enrolling
Updated: 2/21/2018
Scripps Clinic
mi
from
San Diego, CA
Click here to add this to my saved trials
Evaluate Low Doses of AEGR-733 on Hepatic Fat Accumulation by MRS
A Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate Low Doses of the MTP-Inhibitor AEGR-733 on Hepatic Fat Accumulation as Measured by Magnetic Resonance Spectroscopy
Status: Enrolling
Updated:  2/21/2018
Radiant Research
mi
from
Santa Rosa, CA
Evaluate Low Doses of AEGR-733 on Hepatic Fat Accumulation by MRS
A Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate Low Doses of the MTP-Inhibitor AEGR-733 on Hepatic Fat Accumulation as Measured by Magnetic Resonance Spectroscopy
Status: Enrolling
Updated: 2/21/2018
Radiant Research
mi
from
Santa Rosa, CA
Click here to add this to my saved trials
Evaluate Low Doses of AEGR-733 on Hepatic Fat Accumulation by MRS
A Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate Low Doses of the MTP-Inhibitor AEGR-733 on Hepatic Fat Accumulation as Measured by Magnetic Resonance Spectroscopy
Status: Enrolling
Updated:  2/21/2018
MedStar Research Institute
mi
from
Washington,
Evaluate Low Doses of AEGR-733 on Hepatic Fat Accumulation by MRS
A Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate Low Doses of the MTP-Inhibitor AEGR-733 on Hepatic Fat Accumulation as Measured by Magnetic Resonance Spectroscopy
Status: Enrolling
Updated: 2/21/2018
MedStar Research Institute
mi
from
Washington,
Click here to add this to my saved trials
Evaluate Low Doses of AEGR-733 on Hepatic Fat Accumulation by MRS
A Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate Low Doses of the MTP-Inhibitor AEGR-733 on Hepatic Fat Accumulation as Measured by Magnetic Resonance Spectroscopy
Status: Enrolling
Updated:  2/21/2018
Radiant Research Inc.
mi
from
Chicago, IL
Evaluate Low Doses of AEGR-733 on Hepatic Fat Accumulation by MRS
A Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate Low Doses of the MTP-Inhibitor AEGR-733 on Hepatic Fat Accumulation as Measured by Magnetic Resonance Spectroscopy
Status: Enrolling
Updated: 2/21/2018
Radiant Research Inc.
mi
from
Chicago, IL
Click here to add this to my saved trials
Evaluate Low Doses of AEGR-733 on Hepatic Fat Accumulation by MRS
A Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate Low Doses of the MTP-Inhibitor AEGR-733 on Hepatic Fat Accumulation as Measured by Magnetic Resonance Spectroscopy
Status: Enrolling
Updated:  2/21/2018
University of Iowa
mi
from
Iowa City, IA
Evaluate Low Doses of AEGR-733 on Hepatic Fat Accumulation by MRS
A Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate Low Doses of the MTP-Inhibitor AEGR-733 on Hepatic Fat Accumulation as Measured by Magnetic Resonance Spectroscopy
Status: Enrolling
Updated: 2/21/2018
University of Iowa
mi
from
Iowa City, IA
Click here to add this to my saved trials
Evaluate Low Doses of AEGR-733 on Hepatic Fat Accumulation by MRS
A Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate Low Doses of the MTP-Inhibitor AEGR-733 on Hepatic Fat Accumulation as Measured by Magnetic Resonance Spectroscopy
Status: Enrolling
Updated:  2/21/2018
LMARC
mi
from
Louisville, KY
Evaluate Low Doses of AEGR-733 on Hepatic Fat Accumulation by MRS
A Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate Low Doses of the MTP-Inhibitor AEGR-733 on Hepatic Fat Accumulation as Measured by Magnetic Resonance Spectroscopy
Status: Enrolling
Updated: 2/21/2018
LMARC
mi
from
Louisville, KY
Click here to add this to my saved trials
Evaluate Low Doses of AEGR-733 on Hepatic Fat Accumulation by MRS
A Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate Low Doses of the MTP-Inhibitor AEGR-733 on Hepatic Fat Accumulation as Measured by Magnetic Resonance Spectroscopy
Status: Enrolling
Updated:  2/21/2018
Maine Research Associates
mi
from
Auburn, ME
Evaluate Low Doses of AEGR-733 on Hepatic Fat Accumulation by MRS
A Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate Low Doses of the MTP-Inhibitor AEGR-733 on Hepatic Fat Accumulation as Measured by Magnetic Resonance Spectroscopy
Status: Enrolling
Updated: 2/21/2018
Maine Research Associates
mi
from
Auburn, ME
Click here to add this to my saved trials
Evaluate Low Doses of AEGR-733 on Hepatic Fat Accumulation by MRS
A Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate Low Doses of the MTP-Inhibitor AEGR-733 on Hepatic Fat Accumulation as Measured by Magnetic Resonance Spectroscopy
Status: Enrolling
Updated:  2/21/2018
Health Trends Research
mi
from
Baltimore, MD
Evaluate Low Doses of AEGR-733 on Hepatic Fat Accumulation by MRS
A Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate Low Doses of the MTP-Inhibitor AEGR-733 on Hepatic Fat Accumulation as Measured by Magnetic Resonance Spectroscopy
Status: Enrolling
Updated: 2/21/2018
Health Trends Research
mi
from
Baltimore, MD
Click here to add this to my saved trials
Evaluate Low Doses of AEGR-733 on Hepatic Fat Accumulation by MRS
A Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate Low Doses of the MTP-Inhibitor AEGR-733 on Hepatic Fat Accumulation as Measured by Magnetic Resonance Spectroscopy
Status: Enrolling
Updated:  2/21/2018
Johns Hopkins
mi
from
Baltimore, MD
Evaluate Low Doses of AEGR-733 on Hepatic Fat Accumulation by MRS
A Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate Low Doses of the MTP-Inhibitor AEGR-733 on Hepatic Fat Accumulation as Measured by Magnetic Resonance Spectroscopy
Status: Enrolling
Updated: 2/21/2018
Johns Hopkins
mi
from
Baltimore, MD
Click here to add this to my saved trials
Evaluate Low Doses of AEGR-733 on Hepatic Fat Accumulation by MRS
A Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate Low Doses of the MTP-Inhibitor AEGR-733 on Hepatic Fat Accumulation as Measured by Magnetic Resonance Spectroscopy
Status: Enrolling
Updated:  2/21/2018
Washington University School of Medicine
mi
from
Saint Louis, MO
Evaluate Low Doses of AEGR-733 on Hepatic Fat Accumulation by MRS
A Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate Low Doses of the MTP-Inhibitor AEGR-733 on Hepatic Fat Accumulation as Measured by Magnetic Resonance Spectroscopy
Status: Enrolling
Updated: 2/21/2018
Washington University School of Medicine
mi
from
Saint Louis, MO
Click here to add this to my saved trials
Evaluate Low Doses of AEGR-733 on Hepatic Fat Accumulation by MRS
A Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate Low Doses of the MTP-Inhibitor AEGR-733 on Hepatic Fat Accumulation as Measured by Magnetic Resonance Spectroscopy
Status: Enrolling
Updated:  2/21/2018
Sterling Research Group
mi
from
Cincinnati, OH
Evaluate Low Doses of AEGR-733 on Hepatic Fat Accumulation by MRS
A Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate Low Doses of the MTP-Inhibitor AEGR-733 on Hepatic Fat Accumulation as Measured by Magnetic Resonance Spectroscopy
Status: Enrolling
Updated: 2/21/2018
Sterling Research Group
mi
from
Cincinnati, OH
Click here to add this to my saved trials
Evaluate Low Doses of AEGR-733 on Hepatic Fat Accumulation by MRS
A Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate Low Doses of the MTP-Inhibitor AEGR-733 on Hepatic Fat Accumulation as Measured by Magnetic Resonance Spectroscopy
Status: Enrolling
Updated:  2/21/2018
Univ of Pennsylvania
mi
from
Philadelphia, PA
Evaluate Low Doses of AEGR-733 on Hepatic Fat Accumulation by MRS
A Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate Low Doses of the MTP-Inhibitor AEGR-733 on Hepatic Fat Accumulation as Measured by Magnetic Resonance Spectroscopy
Status: Enrolling
Updated: 2/21/2018
Univ of Pennsylvania
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Evaluate Low Doses of AEGR-733 on Hepatic Fat Accumulation by MRS
A Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate Low Doses of the MTP-Inhibitor AEGR-733 on Hepatic Fat Accumulation as Measured by Magnetic Resonance Spectroscopy
Status: Enrolling
Updated:  2/21/2018
Baylor College of Medicine
mi
from
Houston, TX
Evaluate Low Doses of AEGR-733 on Hepatic Fat Accumulation by MRS
A Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate Low Doses of the MTP-Inhibitor AEGR-733 on Hepatic Fat Accumulation as Measured by Magnetic Resonance Spectroscopy
Status: Enrolling
Updated: 2/21/2018
Baylor College of Medicine
mi
from
Houston, TX
Click here to add this to my saved trials
Evaluate Low Doses of AEGR-733 on Hepatic Fat Accumulation by MRS
A Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate Low Doses of the MTP-Inhibitor AEGR-733 on Hepatic Fat Accumulation as Measured by Magnetic Resonance Spectroscopy
Status: Enrolling
Updated:  2/21/2018
Clinical Trial Network
mi
from
Houston, TX
Evaluate Low Doses of AEGR-733 on Hepatic Fat Accumulation by MRS
A Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate Low Doses of the MTP-Inhibitor AEGR-733 on Hepatic Fat Accumulation as Measured by Magnetic Resonance Spectroscopy
Status: Enrolling
Updated: 2/21/2018
Clinical Trial Network
mi
from
Houston, TX
Click here to add this to my saved trials
Evaluate Low Doses of AEGR-733 on Hepatic Fat Accumulation by MRS
A Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate Low Doses of the MTP-Inhibitor AEGR-733 on Hepatic Fat Accumulation as Measured by Magnetic Resonance Spectroscopy
Status: Enrolling
Updated:  2/21/2018
dgd Research, Inc.
mi
from
San Antonio, TX
Evaluate Low Doses of AEGR-733 on Hepatic Fat Accumulation by MRS
A Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate Low Doses of the MTP-Inhibitor AEGR-733 on Hepatic Fat Accumulation as Measured by Magnetic Resonance Spectroscopy
Status: Enrolling
Updated: 2/21/2018
dgd Research, Inc.
mi
from
San Antonio, TX
Click here to add this to my saved trials
Evaluate Safety and Efficacy of AEGR-733 and Atorvastatin vs Atorvastatin Monotherapy in Hypercholesterolemia
A Randomized, Double Blind Comparator-controlled, Parallel-group Study to Evaluate the Safety and Efficacy of the Combination of AEGR-733 and Atorvastatin 20 mg vs Atorvastatin Monotherapy in Subjects With Moderate Hypercholesterolemia
Status: Enrolling
Updated:  2/21/2018
Linda Murray, DO - Radiant Research
mi
from
Pinellas Park, FL
Evaluate Safety and Efficacy of AEGR-733 and Atorvastatin vs Atorvastatin Monotherapy in Hypercholesterolemia
A Randomized, Double Blind Comparator-controlled, Parallel-group Study to Evaluate the Safety and Efficacy of the Combination of AEGR-733 and Atorvastatin 20 mg vs Atorvastatin Monotherapy in Subjects With Moderate Hypercholesterolemia
Status: Enrolling
Updated: 2/21/2018
Linda Murray, DO - Radiant Research
mi
from
Pinellas Park, FL
Click here to add this to my saved trials
Evaluate Safety and Efficacy of AEGR-733 and Atorvastatin vs Atorvastatin Monotherapy in Hypercholesterolemia
A Randomized, Double Blind Comparator-controlled, Parallel-group Study to Evaluate the Safety and Efficacy of the Combination of AEGR-733 and Atorvastatin 20 mg vs Atorvastatin Monotherapy in Subjects With Moderate Hypercholesterolemia
Status: Enrolling
Updated:  2/21/2018
Sheila Rodstein, MD
mi
from
Edina, MN
Evaluate Safety and Efficacy of AEGR-733 and Atorvastatin vs Atorvastatin Monotherapy in Hypercholesterolemia
A Randomized, Double Blind Comparator-controlled, Parallel-group Study to Evaluate the Safety and Efficacy of the Combination of AEGR-733 and Atorvastatin 20 mg vs Atorvastatin Monotherapy in Subjects With Moderate Hypercholesterolemia
Status: Enrolling
Updated: 2/21/2018
Sheila Rodstein, MD
mi
from
Edina, MN
Click here to add this to my saved trials
Evaluate Safety and Efficacy of AEGR-733 and Atorvastatin vs Atorvastatin Monotherapy in Hypercholesterolemia
A Randomized, Double Blind Comparator-controlled, Parallel-group Study to Evaluate the Safety and Efficacy of the Combination of AEGR-733 and Atorvastatin 20 mg vs Atorvastatin Monotherapy in Subjects With Moderate Hypercholesterolemia
Status: Enrolling
Updated:  2/21/2018
Dennis McCluskey, MD - Radiant Research
mi
from
Mogadore, OH
Evaluate Safety and Efficacy of AEGR-733 and Atorvastatin vs Atorvastatin Monotherapy in Hypercholesterolemia
A Randomized, Double Blind Comparator-controlled, Parallel-group Study to Evaluate the Safety and Efficacy of the Combination of AEGR-733 and Atorvastatin 20 mg vs Atorvastatin Monotherapy in Subjects With Moderate Hypercholesterolemia
Status: Enrolling
Updated: 2/21/2018
Dennis McCluskey, MD - Radiant Research
mi
from
Mogadore, OH
Click here to add this to my saved trials
Evaluate Safety and Efficacy of AEGR-733 and Atorvastatin vs Atorvastatin Monotherapy in Hypercholesterolemia
A Randomized, Double Blind Comparator-controlled, Parallel-group Study to Evaluate the Safety and Efficacy of the Combination of AEGR-733 and Atorvastatin 20 mg vs Atorvastatin Monotherapy in Subjects With Moderate Hypercholesterolemia
Status: Enrolling
Updated:  2/21/2018
Michele Reynolds, MD
mi
from
Dallas, TX
Evaluate Safety and Efficacy of AEGR-733 and Atorvastatin vs Atorvastatin Monotherapy in Hypercholesterolemia
A Randomized, Double Blind Comparator-controlled, Parallel-group Study to Evaluate the Safety and Efficacy of the Combination of AEGR-733 and Atorvastatin 20 mg vs Atorvastatin Monotherapy in Subjects With Moderate Hypercholesterolemia
Status: Enrolling
Updated: 2/21/2018
Michele Reynolds, MD
mi
from
Dallas, TX
Click here to add this to my saved trials
Evaluate Safety and Efficacy of AEGR-733 and Atorvastatin vs Atorvastatin Monotherapy in Hypercholesterolemia
A Randomized, Double Blind Comparator-controlled, Parallel-group Study to Evaluate the Safety and Efficacy of the Combination of AEGR-733 and Atorvastatin 20 mg vs Atorvastatin Monotherapy in Subjects With Moderate Hypercholesterolemia
Status: Enrolling
Updated:  2/21/2018
William Jennings, MD - Radiant Research
mi
from
San Antonio, TX
Evaluate Safety and Efficacy of AEGR-733 and Atorvastatin vs Atorvastatin Monotherapy in Hypercholesterolemia
A Randomized, Double Blind Comparator-controlled, Parallel-group Study to Evaluate the Safety and Efficacy of the Combination of AEGR-733 and Atorvastatin 20 mg vs Atorvastatin Monotherapy in Subjects With Moderate Hypercholesterolemia
Status: Enrolling
Updated: 2/21/2018
William Jennings, MD - Radiant Research
mi
from
San Antonio, TX
Click here to add this to my saved trials
AEGR-733 and Atorvastatin 20 mg vs. Monotherapy in Moderate Hypercholesterolemia
A Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Evaluate the Safety and Efficacy of the Combination of AEGR-733 (Formerly BMS201038) and Atorvastatin 20 mg vs. Monotherapy in Subjects With Moderate Hypercholesterolemia
Status: Enrolling
Updated:  2/21/2018
Medical Affiliated Research Center, Inc.
mi
from
Huntsville, AL
AEGR-733 and Atorvastatin 20 mg vs. Monotherapy in Moderate Hypercholesterolemia
A Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Evaluate the Safety and Efficacy of the Combination of AEGR-733 (Formerly BMS201038) and Atorvastatin 20 mg vs. Monotherapy in Subjects With Moderate Hypercholesterolemia
Status: Enrolling
Updated: 2/21/2018
Medical Affiliated Research Center, Inc.
mi
from
Huntsville, AL
Click here to add this to my saved trials